



SOCIETY for
Glycobiology

2022 Annual Meeting

NOVEMBER 14–18, 2022

VIRTUAL CONFERENCE



THANK YOU TO OUR SPONSORS

PLATINUM SPONSOR



GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



GENERAL SPONSORS





SfG CONFERENCE APP

Have you downloaded the SfG conference app yet?

Connect with other attendees, view the agenda, set up meetings, and more!

How to find the app:

Search Whova in Apple Store (iOS) and Google Play Store (Android) and use the email address you registered for the conference with to sign up.





SCHEDULE OF EVENTS

Monday, November 14

10:00 am - 10:10 am

Conference Opening Remarks

Vlad Panin, Texas A&M University, SfG President

10:10 am - 11:45 am

Session 1: Glycans in Development, Physiology, and Evolution

Session Chair: Hamed Jafar-Nejad, BCM, Houston

Keynote Speakers:

Robert Haltiwanger, UGA

Muriel Bardor, University of Rouen, France

Hamed Jafar-Nejad, BCM, Houston

Poster Talks:

Chelsea Painter, UCSD

Carl Fogarty, Maynooth University, Ireland

Francesca Boscolo Sesillo, UCSD

Christopher West, UGA

11:45 am - 12:00 pm

Coffee Break - Panel Discussion

12:00 pm - 1:30 pm

Session 2: Karl Meyer and Rosalind Kornfeld Awards

Karl Meyer Lectureship Award

Gabriel Rabinovich, University of Buenos Aires, Argentina

Rosalind Kornfeld Award for Lifetime Achievement in Glycobiology

Anne Imberty, Grenoble Alpes University, France

1:30 pm - 3:00 pm

LUNCH BREAK

3:00 pm - 4:40 pm

Session 3: Glycan Biosynthesis, Trafficking, and Signaling

Session Chair: Karen Colley, University of Illinois Chicago

Keynote Speakers:

Ellen Sidransky, NIH/NHGRI

Yanzhuang Wang, University of Michigan

Richa Sardana, Cornell University

Poster Talks:

Fawsi Khoder-Agha, Univ of Copenhagen

Mike Boyce, Duke University

Willie Vann, CBER/FDA

Jeffrey Brown, Washington University

4:40 pm - 5:00 pm

Coffee Break - Panel Discussion



Tuesday, November 15

10:00 am - 11:45 am

Session 4: Pathogen-Host Interactions & Glycoimmunology
Session Chair: Richard Cummings, Harvard

Keynote Speakers:

Yvette van Kooyk, Amsterdam
Christine Szymanski, CCRC UGA
Victor Nizet, UCSD
Chuck Dimitroff, FIU

Poster Talks:

Kurt Drickamer, Imperial College of London
Anabel Gonzalez-Gil, Johns Hopkins University
Ashley Rogers, UGA

12:00 pm - 12:15 pm

Coffee Break - Panel Discussion

12:15 pm - 1:45 pm

Session 5: Glycobiology Significant Achievement & President's Innovator Awards

Glycobiology Significant Achievement Award
Fikri Avci, Emory University

President's Innovator Award

James Paulson, The Scripps Research Institute

1:45 pm - 2:45 pm

LUNCH BREAK

2:45 pm - 4:30 pm

Session 6: Glycopathologies
Session Chair: Lance Wells, CCRC, UGA

Keynote Speakers:

Heather Flanagan-Steele, Greenwood Genetic Center
Dirk Lefeber, Radboud University, the Netherlands
Lance Wells, CCRC, UGA
Ramon Sun, University of Florida

Poster Talks:

Eve Prodoehl, Medical College of Wisconsin
Rajindra Aryal, Harvard
Amy Attaway, Cleveland Clinic

4:30 pm - 4:45 pm

Coffee Break - Panel Discussion

4:55pm - 6:30 pm

Poster Session 1 and Exhibits



Wednesday, November 16

10:00 am - 11:45am

Session 7: Neuroglycobiology
Session Chair: Kenji Kadomatsu, Nagoya University, Japan

Keynote Speakers:

Hannes Buelow, Albert Einstein College of Medicine
William Green, University of Chicago
Kenji Kadomatsu, Nagoya University, Japan

Poster Talks:

Rameen Shah, Mayo Clinic
Andrew Edmondson, Children's Hospital of Philadelphia
Pedro Monagas-Valentin, Texas A&M
Maxence Noel, Harvard

11:45 am - 12:00 pm

Coffee Break - Panel Discussion

12:00 pm - 1:45 pm

Session 8: Chemical Biology and Structure-Function Studies
Session Chair: Jennifer Kohler, UT Southwestern

Keynote Speakers:

Christina Woo, Harvard University
Jennifer Kohler, UT Southwestern
Katrine Schjoldager, University of Copenhagen
Katharina Ribbeck, MIT

Poster Talks:

Chantelle Capicciotti, Queen's University
Jonathan Du, Emory
Ana Ramirez, ETH Zurich

1:55 pm - 2:10 pm

Coffee Break - Panel Discussion

LUNCH BREAK

3:20 pm - 4:00 pm

**Session 9: SfG Distinguished Service and
MCP/ ASBMB Lectureship Awards**

SfG Distinguished Service Award
Parastoo Azadi, CCRC, UGA

MCP/ASBMB Lectureship Award
Carlito Lebrilla, UC Davis

4:00 pm - 5:45 pm

Poster Session II and Exhibits

Thursday, November 17

10:00 am - 11:45 am

Session 10: IGO Guest Session. Diversity of Pathways and Structures
Session Chair: **Adnan Halim**, University of Copenhagen

Keynote Speakers:

Iain Wilson, BOKU, Austria

Thierry Hennet, University of Zurich, Switzerland **Stephen Withers**,
University of British Columbia, Canada **Adnan Halim**, University of
Copenhagen

Poster Talks:

Kaspar Locher, ETH Zurich

Yohei Tsukamoto, Nagoya University

Julian Ugonotti, Macquarie University

11:55 am - 12:10 pm

Coffee Break - Panel Discussion

12:10 pm - 1:50 pm

Session 11: Novel Tools and Approaches

Session Chair: **Elisa Fadda**, Maynooth University, Ireland

Keynote Speakers:

Sander van Kasteren, Leiden, University, Sweden

Kiyoko Aoki-Kinoshita, Soka University, Japan

John Klassen, University of Alberta, Canada

Daniel Bojar, University of Gothenburg, Sweden

Poster Talks:

Kayla Bastian, Newcastle University

James Prestegard, UGA

Nicholas Riley, Stanford

2:05 pm - 2:20 pm

Coffee Break - Panel Discussion

3:20 pm - 5:40 pm

Session 12: NIH Q&A Information Session

Pamela Marino, Chair

SFG Business Meeting

Dataworks - FASEB Info Session

Poster Award Announcement

Conference Closing Remarks

Vlad Panin, Texas A&M University, SfG President

**SOCIETY FOR GLYCOBIOLOGY AWARDS****Karl Meyer Lectureship Award**

The Karl Meyer Lectureship Award was established in 1990 to honor the distinguished career of Karl Meyer and his outstanding contributions to the field of glycobiology. This international award is given to well-established scientists with currently active research programs who have made widely recognized major contributions to the field of glycobiology.

The 2022 Karl Meyer Lectureship Award will be presented to **Dr. Gabriel A. Rabinovich**. Dr. Rabinovich is director of the Laboratory of Glycomedicine at the Institute of Biology and Experimental Medicine (IBYME) at the Consejo Nacional de Investigaciones Científicas (CONICET), Buenos Aires, Argentina, and professor of immunology at the Faculty of Exact and Natural Sciences at the University of Buenos Aires. Dr. Rabinovich conducted both his undergraduate and doctoral studies at the Faculty of Chemical Sciences at the National University of Córdoba. Starting from an unexpected discovery in the early 1990s involving the identification of galectin-1 in cells of the monocyte/macrophage lineage, Dr. Rabinovich embarked on a long journey dedicated to exploring the functions of this glycan-binding protein as well as other members of the galectin family in the regulation of innate and adaptive immune responses. In 1999, he moved to Buenos Aires, where he carried out postdoctoral studies and immediately became an independent investigator.



Over the course of more than three decades, Dr. Rabinovich has established himself worldwide as a leading scientist in glycosciences, making highly significant, paradigm-shifting observations—from the very basic mechanisms involved in the activity of galectins and their glycosylated ligands on regulation of immune homeostasis to translational aspects relevant to cancer, autoimmune inflammation, microbial infection, and other elements of human health and disease. As a result of his efforts and those of his team, Dr. Rabinovich demonstrated that endogenous galectins can translate glycan-encoded information into novel regulatory programs that control tumor immunity, promote resolution of inflammation and autoimmune diseases, induce fetomaternal tolerance, sustain angiogenesis, modulate cardiovascular pathology, and control host-pathogen interactions by regulating the fate and function of different cell types.

It is noteworthy that Dr. Rabinovich has developed his scientific career entirely in Argentina, where he successfully established a broad multidisciplinary research program in the field of glycosciences. His contributions, reflected in more than 300 widely cited publications, mostly in high-profile journals, as well as several awarded patents, have led to the discovery of novel findings and development of innovative technologies. This translational potential has inspired Dr. Rabinovich and his team to create a biotech platform called “Galtec Life” focused on the design, early development, and clinical validation of next generation galectin-based therapeutics.

Recognition of Dr. Rabinovich’s standing within the international scientific community has led to his appointment as an international member of the National Academy in the United States in 2016, the Third World Academy of Science (TWAS) in 2014, and the European Molecular Biology Organization (EMBO) in 2022. He has also received the highest national scientific honors, including “Outstanding Investigator of Argentina” and the Konex and Bunge & Born Awards. Additionally, he has worked to increase the visibility of glycobiology worldwide by organizing and co-organizing several training courses and scientific meetings, including the First Keystone Meeting in Glycoimmunology in Lake Louise (Canada) and the Glycoimmunology Conference in the context of the World Congress of Immunology in Rio de Janeiro (Brazil). He also has generously shared his expertise and resources with the scientific community, helping to expand glycobiology into established fields, including immunology, oncology, neurobiology, cardiovascular research, hematology, and microbiology. In this regard, he has delivered more than 400 lectures worldwide at prestigious scientific conferences, including Gordon, Keystone, Sapporo, EMBO, HHMI, Jenner, and Cell Press. His work has been supported by prestigious national and international agencies, and he serves as an editorial board member or associate editor of several high-profile journals. Finally, Dr. Rabinovich has promoted and expanded the field of glycobiology by training numerous students and fellows in Argentina and South America, including undergraduate, graduate, and Ph.D. students as well as postdoctoral fellows and research associates.

In summary, Dr. Rabinovich’s scientific contributions have been at the forefront of the glycosciences, and his work continues to inspire others inside and outside the field. He is an active, outstanding, and generous scientist with a strong commitment to scientific progress in all areas of basic and translational research, education, mentoring, and service to the community. Thus, Dr. Rabinovich is a highly deserving recipient of the 2022 Karl Meyer Lectureship Award, the highest award given by SFG.

Rosalind Kornfeld Award for Lifetime Achievement in Glycobiology

The Rosalind Kornfeld Award for Lifetime Achievement in Glycobiology was established in 2008 to honor Dr. Rosalind Kornfeld's distinguished scientific career and service to the Society. The Society bestows this prestigious award to scientists who, throughout their professional careers, have made outstanding contributions to glycobiology.

The recipient of the 2022 Rosalind Kornfeld Award for Lifetime Achievement in Glycobiology is **Dr. Anne Imberty**, senior researcher at and former director of the Centre de Recherche sur les Macromolécules Végétales (CERMAV) in Grenoble and founder of the Glyco@Alps network. From the start of her career, Dr. Imberty has had a strong impact on the field of glycobiology. As a graduate student, she solved the structures of the crystalline parts of starch granules, proposing a three-dimensional arrangement of amylose and amylopectin constituents. These results still serve as a notable reference in our field. She earned her doctorate at the Centre National de la Recherche Scientifique in Grenoble in 1988. Through postdoctoral positions in Toronto, Nantes, and Grenoble in the 1990s she widened her repertoire of 3D glycan structures to include N-linked glycans and blood group antigens, among others. These studies naturally led to an interest in the structural biology of glycan-protein interactions, particularly lectins, and in 1999, Dr. Imberty became head of the Molecular Glycobiology group at CERMAV in Grenoble, where she was the director from 2016–2020.



Dr. Imberty's impact can be seen through two major contributions: her seminal work on soluble calcium-dependent bacterial lectins and their interactions with glycan ligands, and methodology development for structural glycobiology. Her work characterizing such lectins in the bacterium *Pseudomonas aeruginosa* is a strong example of the importance of her discoveries. These lectins have an important role in infection in cystic fibrosis patients. Her work stimulated several teams of synthetic carbohydrate chemists to develop carbohydrate-based anti-infective therapeutics directed against these lectins.

Dr. Imberty developed the now commonly used strategy of integrating information from biochemical techniques (e.g., microcalorimetry, surface plasmon resonance, microarrays, mutational analysis) with crystallographic data to gain a more thorough understanding of lectin-glycan interfaces and has been particularly influential in the drive to make results of structural determinations for carbohydrates readily available to the research community. These methodological innovations have been critical in advancing the field of structural glycobiology, which has been hampered by a lack of the tools that peptide and protein researchers take for granted in the field of molecular modeling and methods for structural determination. In addition, Dr. Imberty has created several important scientific resources for glycobiologists. These include, with Dr. Frederique Lisacek, UniLectin3D (<https://www.unilectin.eu/>), a database of structures of glycan binding proteins, and LectomeXplore, which enables prediction of lectins in all species, including the micro-organisms that make up the human microbiome. In addition, Dr. Imberty has supported the traditional modes of data distribution by her involvement in SfG's Publication Committee and as an editor of *Glycobiology*.

In 2014, Dr. Imberty was made a Chevalier de la Légion d'Honneur for her scientific work. She has also received numerous awards, including the Catalán-Sabatier International Prize by the Spanish Royal Society of Chemistry in 2020 and the Roy L. Whistler Award by the International Carbohydrate Organization in 2004.

Dr. Imberty is a true leader and pioneer in glycobiology and a very deserving recipient of the 2022 Rosalind Kornfeld Award.



Glycobiology Significant Achievement Award

The Glycobiology Significant Achievement Award is given annually by Oxford University Press (publisher of *Glycobiology*) to honor new or mid-career scientists who have made key discoveries during their early careers with the potential to have a substantial impact on the glycoscience community.

Oxford is delighted to present the 2022 Glycobiology Significant Achievement Award to **Dr. Fikri Avci**, who has served as an associate professor in the Center for Molecular Medicine and Department of Biochemistry and Molecular Biology at the University of Georgia. He recently moved his laboratory to the Department of Biochemistry and Emory Vaccine Center at the Emory University School of Medicine.

Dr. Avci has established an exceptionally productive and highly interdisciplinary research group addressing problems at the interface of glycobiology and immunology and is now a leader in the field of glycoimmunology. His postdoctoral work published in *Nature Medicine* (Avci et al., 2011) was a breakthrough in the field and served as the foundation for his successful research program. Dr. Avci and his colleagues described the molecular and cellular mechanisms for T-cell recruitment by glycoconjugate vaccines. This seminal and paradigm-shifting work has been highlighted in various print and online media and has had direct and indirect impacts on novel strategies for vaccine development. The strength of his group has been rooted in exploring mechanisms of effector immune responses induced by bacterial (e.g., *Streptococcus pneumoniae*) and viral (e.g., HIV) pathogens through their surface glycoconjugates. Dr. Avci's work has direct relevance to the design of a new generation of vaccines against these devastating pathogens. In one study, his research group identified new T cell-specific immune mechanisms induced by HIV envelope glycoprotein, which offered a foundation for developing a protective AIDS vaccine (*Nature Comm*, 2020). In another key discovery, Dr. Avci's research group demonstrated that host protein glycosylation can be detrimental to nucleic acid vaccine design (*PNAS*, 2020). More recently, his research group elucidated the impact of immune suppressants used clinically on SARS-CoV-2 vaccine efficacy (*Vaccine*, 2022). His group's work on bacterial polysaccharides and conjugate vaccines against bacterial pathogens yielded many important discoveries published in reputable journals, such as *mBio*, *JBC*, *Ji*, and *Glycobiology*. The Avci lab also identified and developed a pneumococcal polysaccharide-degrading enzyme, which is currently being investigated in preclinical studies as a biological antibacterial drug target through a federally and privately funded startup company that Dr. Avci founded. Dr. Avci's infectious disease and vaccine research could not have been more relevant and important in this time of the COVID-19 pandemic. His research group also has very exciting new findings in cancer immunology and gut microbiome research. Dr. Avci's achievements to date foretell continuing success in his research program to make truly impactful contributions in immunology and glycobiology with direct implications for human health. Thus, Dr. Avci is an emerging leader in a highly important research field. He also has been an exemplary citizen in the service of his scientific community. He has organized many symposia and conferences and served on the editorial boards of multiple journals, including *Glycobiology*.

Oxford is proud to honor Dr. Avci as this year's Glycobiology Significant Achievement Awardee.



President's Innovator Award

The President's Innovator Award acknowledges the contributions of one scientist each year who has made a significant impact on society. The 2022 President's Innovator Award will be presented to **Dr. James Paulson**. Dr. Paulson is the Cecil H. and Ida Green Professor and chair of the Department of Molecular Medicine and Department of Immunology and Microbiology at The Scripps Research Institute in La Jolla, California.

Dr. Paulson received his M.S. (1971) and Ph.D. (1974) in biochemistry at the University of Illinois, Champaign-Urbana. After postdoctoral studies in biochemistry at Duke University Medical Center, he became an assistant professor of biological chemistry at UCLA School of Medicine in 1978, where he was promoted to associate professor in 1981 and professor in 1985. He worked at the Cytel Corporation in San Diego from 1990–1999 as vice president, chief scientific officer, and member of the board of directors. Dr. Paulson joined The Scripps Research Institute as professor in 1999 and from 2001–2012 was director of the Consortium for Functional Glycomics, which grew to over 700 members worldwide. He served as president and acting CEO of The Scripps Research Institute in 2014–2015.



Dr. Paulson is recognized as one of the most influential world leaders in the field of glycobiology. He has published nearly 400 papers and made numerous seminal contributions in the areas of chemical biology of glycans, biochemical genetics of sialyltransferases, and functions of lectins and carbohydrates in immune system and virus-host interactions. For over 40 years, Dr. Paulson's role as a research leader influenced the careers of several generations of scientists in the area of glycobiology and beyond. His work has had enduring impact on the field and on SfG while opening many new avenues in biomedical glycoscience.

Since the 1970s, Dr. Paulson's main research interests have evolved around the functions of sialic acids, arguably the most complex and diverse type of sugar residues, with a multitude of biological functions. His specific interest in creating novel tools for uncovering carbohydrate-binding proteins brought about important discoveries in applied and foundational glycoscience. He was among the pioneers of chemoenzymatic synthesis of sialylated carbohydrates, the approach that led to his breakthrough success in cloning the first sialyltransferase and producing recombinant enzymes. Dr. Paulson's work in this area established a novel direction of research on the structure-function relationship of glycosylation enzymes and promoted a new era of tools based on glycan arrays. His cutting-edge work in the area of chemical glycobiology continues to lead to discoveries and innovation, including the development of unique carbohydrate analogues for inhibition of specific glycosylation pathways; modulation of lectin interactions; and engineering nanoparticles, polymers, and proteins to carry glycan ligands of immune receptors to modulate immune responses.

Dr. Paulson has also made significant contributions that revealed the glycan-mediated mechanism of influenza virus interactions with host cells. His early discovery that influenza virus recognition of sialoside receptors on host cells correlated with species of origin led to advances in the understanding of viral tropism and the structural biology of virus-host interactions. Subsequent research from his laboratory, as well as fruitful collaborations, showed that new human pandemic viruses from avian strains needed to adapt their receptor specificity for transmission in the human population. Dr. Paulson's innovative contributions to glycovirology have similarly contributed to knowledge of receptors of polyoma viruses and coronaviruses. More recently, his laboratory designed a unique method for fingerprinting HIV glycans to support the development of effective vaccines. These conceptual and methodological advances are making all-important contributions to biomedicine in the wake of recent viral pandemics.

Dr. Paulson's research on the glycan ligands of the selectin and Siglec families of immune cell receptors and understanding their biological functions are among the most significant advances in the field of glycoimmunology. A central theme of this work was generating novel, high-affinity ligands that can discriminate between carbohydrate binding proteins, thereby providing new avenues to specifically target clinically important inflammatory pathways with potential for treatments of immune system disorders. Dr. Paulson's research in this area has made an impactful contribution to foundational glycoscience as well as the area of therapeutic applications for autoimmune disorders and cancer.

Dr. Paulson's scientific contributions have been recognized by many prestigious awards, including the ACS Melville L. Wolfrom and Claude S. Hudson Awards, the SfG Karl Meyer Award, the Bijvoet Medal, and the U.S. EPA Green Chemistry Challenge Award. He was also elected a Fellow of the American Association for the Advancement of Science.

For his seminal contributions to foundational glycoscience and innovative applications of chemical biology and glycoengineering in biomedicine, Dr. Paulson has been awarded the 2022 President's Innovator Award from SfG.



Molecular and Cellular Proteomics/American Society for Biochemistry and Molecular Biology Lectureship Award

The 2022 Molecular and Cellular Proteomics (MCP)/American Society for Biochemistry and Molecular Biology (ASBMB) Lectureship Award is will be presented to **Dr. Carlito Lebrilla** during this year's Society for Glycobiology Annual Meeting. The *Molecular & Cellular Proteomics* journal was created in 2001 to address the growing needs of the proteomics community. The MCP/ASBMB award was established in 2013 to honor scientists who have been at the forefront of the emerging field of glycomics and glycoproteomics.

Dr. Lebrilla is a Distinguished Professor of Chemistry at the University of California, Davis, where he formerly served as chair of the department. He received a B.S. in chemistry from the University of California, Irvine and his Ph.D. in physical organic chemistry from the University of California, Berkeley. This was followed by gas-phase chemistry research at the Technical University in Berlin as an Alexander von Humboldt Fellow and an NSF-NATO Fellow. He returned to the University of California, Irvine as a President's Fellow studying Fourier transform ion cyclotron resonance mass spectrometry before moving to the University of California, Davis in 1989 to establish his own laboratory.

During his independent career, Dr. Lebrilla has been a pioneer in the use of mass spectrometry to analyze glycans and glycoconjugates. This has resulted in more than 400 peer-reviewed publications, recognition as a Fellow of the American Association for the Advancement of Science, and service on multiple mass spectrometry-related editorial boards, including the board of Molecular and Cellular Proteomics. Dr. Lebrilla is also an entrepreneur and is the co-founder of multiple startup companies.

Dr. Lebrilla is well known for tackling technically challenging questions related to human health. A major long-term focus area in his lab has been developing and applying glycomic approaches aimed at identifying and validating early biomarkers of disease, specifically ovarian, breast, and prostate cancer. His laboratory is also a leader in characterizing the components of human milk, including oligosaccharides, in an effort to identify bioactive molecules and develop improved nutrient supplements. For his long-term commitment to studying glycoconjugates by cutting-edge mass spectrometry, Dr. Lebrilla was chosen by the editorial leadership of the MCP to receive the 2022 Lectureship Award.



SfG Distinguished Service Award

In 2021, the SfG board of directors established the Distinguished Service Award, which is intended for individuals with a sustained record of distinguished service to SfG and/or the glycobiology community. In 2022, the board has unanimously selected **Dr. Parastoo Azadi** as the recipient of the SfG Distinguished Service Award.

Dr. Azadi was born in Iran and immigrated to the United Kingdom in 1978. She received her B.Sc. in chemistry in 1987 from the University of North London and her Ph.D. in biochemistry in 1991 from Imperial College of Science and Technology, University of London, studying structural characterization of carbohydrates and glycoproteins by mass spectrometry under the supervision of professors A. Dell and H.R. Morris. From 1990–1994 she was the senior scientist and study director at M-Scan Ltd., an analytical mass spectrometry consultancy in the United Kingdom, where she performed structural characterization of native and recombinant glycoproteins using mass spectrometry as a service to the pharmaceutical industry.



Dr. Azadi joined the Complex Carbohydrate Research Center (CCRC) in 1994 as a postdoctoral fellow in the laboratory of Drs. Albersheim and Darvill and studied the effect of the enzymes endohyalase and endolyase on rhamnogalacturonan I. She also became involved in CCRC's service and training activities and became its technical director in 2001 and executive technical director in 2017. In this role, she supervised training and service for three federally funded centers—the DOE Center for Plant and Microbial Complex Carbohydrates, the NIH Resource Center for Integrated Glycotechnology, and the NIH Resource Center for Biomedical Glycomics. In 2021, she was promoted to associate director of the Complex Carbohydrate Research Center for Analytical Service, Training, and Dissemination. She is currently principal investigator for the NIH National Resource Center in Glycoscience and the Department of Energy Center for Plant and Microbial Complex Carbohydrates. She is also co-investigator and director of analytical characterization for GlycoMIP, an NSF-funded material innovation platform.


Dr. Azadi has offered research, service, and hands-on training to the larger scientific community and has ensured that new technologies are disseminated to investigators in the glycobiology community. She has realized that building a world-renowned service and training center requires engagement with many different facets of the scientific community. To that end, she has developed important collaborations with many national and international partners, including biotechnology, pharmaceutical, food, and biofuel companies, as well as with the FDA and U.S. Pharmacopeia. She has also been instrumental in engaging the larger scientific community in understanding the great challenges we face in the structural characterization of glycoconjugates and the associated requirements for ever-changing technologies and tools. Dr. Azadi's group has collaborated with over 2,000 investigators from both nonprofit institutions and industry on characterization of glycans and has helped train over 6,000 scientists as part of CCRC's annual hands-on training courses. Thus, she has had a broad impact on glycobiology, not only by facilitating education and training in complex technical aspects of the field but also by contributing to many studies on the role of carbohydrates in various aspects of biology, which is at the heart of SfG's endeavor. Considering its intent, Dr. Azadi's accomplishments make her an obvious and highly deserving recipient of the 2022 SfG Distinguished Service Award.



TRAVEL AWARD WINNERS

The Society for Glycobiology's Student Travel Awards are given to help students and post-doctoral fellows gain the experience and exposure that comes from attending and presenting at SFG conferences.

Fathima Zahra Abdul Nawaz	Emory University
Trevor Adams	University of Georgia
Ramya Ayyalasomayajula	Florida Atlantic University
Jonathan Babulic	Queen's University
Collin Ballard	Case Western Reserve University
Erik Bidstrup	Cornell University
Donovan Cantrell	University of Georgia
Carl Fogarty	Maynooth University
Leandre Glendenning	Case Western Reserve University
Barnita Haldar	University of Alabama Birmingham
Benjamin Haslund-Gourley	Drexel College of Medicine
Qiang Hu	Texas A&M University
Jihye Hwang	University of Alabama Birmingham
Muddassar Iqbal	University of Maryland
Nicholas Kegley	University of Georgia
Melissa Koff	Texas A&M University
Matthew Kudelka	Memorial Sloan Kettering
Emily Kukan	Case Western Reserve University
Paige LaMore	University of Georgia
Lee Seng Lau	Florida International University
Lucas Loffredo	Columbia University
Dongli Lu	Harvard Medical School
Karina Martinez	George Washington University
Pedro Monagas-Valentin	Texas A&M University
Maxence Noel	Harvard Medical School
Lauren Pepi	University of Georgia
Lorenzo Povo	University of Copenhagen
Beatriz Praena Garcia	University of Missouri
Nicholas Riley	Stanford University
Ashley Rogers	University of Georgia
Priyanka Samanta	University of Mississippi
Edward Schmidt	University of Alberta
Yogita Sharma	Stanford University
Yohei Tsukamoto	Nagoya University
Julian Ugonotti	Macquarie University
Aarya Venkat	University of Georgia
Tin Long Wong	Roswell Park
Shang-Chuen Wu	Harvard



1973-2023



ANNIVERSARY

2023 ANNUAL MEETING

SOCIETY for Glycobiology

Hawaii NOV. 5-8
2023

HILTON WAIKOLOA VILLAGE RESORT BIG ISLAND